KalVista Pharmaceuticals (NASDAQ:KALV) CFO Brian Piekos Sells 4,471 Shares of Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CFO Brian Piekos sold 4,471 shares of the stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $13.45, for a total transaction of $60,134.95. Following the completion of the transaction, the chief financial officer directly owned 10,529 shares in the company, valued at $141,615.05. The trade was a 29.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

KalVista Pharmaceuticals Stock Performance

KALV traded up $0.82 on Thursday, reaching $14.10. The company had a trading volume of 1,928,887 shares, compared to its average volume of 933,997. The company’s fifty day moving average is $12.04 and its 200 day moving average is $12.87. The stock has a market cap of $712.70 million, a P/E ratio of -3.58 and a beta of -0.04. KalVista Pharmaceuticals, Inc. has a fifty-two week low of $7.30 and a fifty-two week high of $17.28.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its earnings results on Monday, November 10th. The specialty pharmaceutical company reported ($0.92) EPS for the quarter, beating the consensus estimate of ($0.96) by $0.04. The firm had revenue of $13.69 million during the quarter, compared to analyst estimates of $6.03 million. On average, sell-side analysts expect that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current year.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Hedge funds have recently modified their holdings of the company. Earned Wealth Advisors LLC bought a new stake in shares of KalVista Pharmaceuticals in the first quarter worth $44,000. BNP Paribas Financial Markets raised its stake in KalVista Pharmaceuticals by 47.0% during the second quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock worth $46,000 after buying an additional 1,292 shares during the last quarter. CWM LLC lifted its holdings in KalVista Pharmaceuticals by 12,636.1% in the first quarter. CWM LLC now owns 4,585 shares of the specialty pharmaceutical company’s stock valued at $53,000 after buying an additional 4,549 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in KalVista Pharmaceuticals during the third quarter valued at $55,000. Finally, Wolverine Asset Management LLC acquired a new stake in KalVista Pharmaceuticals during the third quarter worth approximately $57,000.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on KALV. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Wednesday, October 8th. JMP Securities upped their price objective on shares of KalVista Pharmaceuticals from $27.00 to $28.00 and gave the stock a “market outperform” rating in a research report on Friday, September 12th. Citizens Jmp reduced their price objective on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a research note on Tuesday, November 11th. Needham & Company LLC restated a “buy” rating and issued a $28.00 target price on shares of KalVista Pharmaceuticals in a research report on Friday, September 12th. Finally, Citigroup reiterated a “market outperform” rating on shares of KalVista Pharmaceuticals in a research report on Tuesday, November 11th. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, KalVista Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $26.63.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).